Modified immune-modulating particles

• US 10,471,093 B2
• Filed: 02/17/2015
• Issued: 11/12/2019
• Est. Priority Date: 11/12/2010
• Status: Active Grant

• Current Assignee: Oncour Pharma, Inc.
• Original Assignee: COUR Pharmaceuticals Development Company
• Inventors: Getts, Daniel R., Terry, Rachael, King, Nicholas
• Primary Examiner(s): Browe, David
• Application Number:
  US14/624,461
• Publication Number:
  US 20150174155A1
• Time in Patent Office: 1,729 Days
• Field of Search: None
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/765 Polymers containing oxygen
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 11/02 Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: Y02A 50/30 : Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
• CPC Class Codes: Y10T 428/2982 : Particulate matter [e.g., sphere, flake, etc.]

Abstract

The current invention involves the surprising finding that when carboxylated particles, such as carboxylated polystyrene, PLGA, or diamond particles are administered to subjects, inflammatory immune responses are ameliorated. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same carboxylated particles.

Claims

1. A method of ameliorating an inflammatory immune response in a subject in need thereof comprising intravenously administering to the subject a pharmaceutical composition comprising poly(lactic-co-glycolic acid) (PLGA) particles that have been modified to contain one or more carboxyl groups on the particle'"'"'s surface, wherein the particles do not comprise one or more therapeutically active ingredients.

2. The method of claim 1, wherein the particles are spherical particles.

3. The method of claim 2, wherein the particles have a diameter of between about 0.1 μ

m to about 10 μ

m.

4. The method of claim 2, wherein the particles have a diameter of between about 0.3 μ

m to about 5 μ

m.

5. The method of claim 2, wherein the particles have a diameter of between about 0.5 μ

m to about 1 μ

m.

6. The method of claim 2, wherein the particles have a diameter of about 0.5 μ

m.

7. The method of claim 1, wherein the subject has a viral infection.

8. The method of claim 7, wherein the viral infection is a West Nile Virus infection.

9. The method of claim 1, wherein the PLGA particles have been modified from naked PLGA particles.